SCHEMBL2017965

SCHEMBL2017965

CCOc1cccc(-c2nnc(-c3cn4c5c(cccc35)CCC4)o2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 4/20 0.42
SMN1; SMN2 Q16637 4/20 0.42
ALDH1A1 P00352 6/20 0.41
TSHR P16473 4/20 0.41
NPSR1 Q6W5P4 2/20 0.41
MAPK1 P28482 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
KDM4E B2RXH2 6/20 0.40
HPGD P15428 5/20 0.40
RAB9A P51151 4/20 0.40
NPC1 O15118 3/20 0.40
HSD17B10 Q99714 4/20 0.40
MAPT P10636 4/20 0.40
HTT P42858 1/20 0.40
PDE7A Q13946 1/20 0.39
PDE3A Q14432 1/20 0.39
PDE10A Q9Y233 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2023138 0.89 KDM4E (0.48) TP53SMN1; SMN2ALDH1A1TSHRNPSR1
SCHEMBL2015370 0.83 NPC1 (0.48) TP53SMN1; SMN2ALDH1A1TSHRNPSR1
SCHEMBL2021453 0.82 RAB9A (0.49) SMN1; SMN2ALDH1A1TSHRMAPK1MEN1
SCHEMBL2020106 0.81 RAB9A (0.48) TP53SMN1; SMN2ALDH1A1TSHRNPSR1
SCHEMBL2021806 0.81 ALDH1A1 (0.44) SMN1; SMN2ALDH1A1TSHRMEN1KMT2A
SCHEMBL2019393 0.81 HTR2A (0.43) SMN1; SMN2ALDH1A1TSHRMEN1KMT2A
SCHEMBL2020405 0.79 NPC1 (0.43) SMN1; SMN2ALDH1A1TSHRNPSR1MEN1
SCHEMBL2015078 0.79 HTR2A (0.43) SMN1; SMN2ALDH1A1MEN1KMT2AKDM4E
SCHEMBL2015858 0.77 RAB9A (0.48) TP53SMN1; SMN2ALDH1A1TSHRNPSR1
SCHEMBL2020602 0.77 NPC1 (0.44) TP53SMN1; SMN2ALDH1A1TSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8563567-B2 Substituted heterocyclic compounds ARQULE, INC. (US) 2013-10-22 US disclosed
US-8563567-B2 Substituted heterocyclic compounds ARQULE, INC. (US) 2013-10-22 US disclosed
US-8563567-B2 Substituted heterocyclic compounds ARQULE, INC. (US) 2013-10-22 US disclosed
WO-2011082266-A2 SUBSTITUTED HETEROCYCLIC COMPOUNDS ARQULE, INC. (US) 2011-07-07 WO disclosed
US-20110160237-A1 Substituted Heterocyclic Compounds ARQULE, INC. (US) 2011-06-30 US disclosed
US-20110160237-A1 Substituted Heterocyclic Compounds ARQULE, INC. (US) 2011-06-30 US disclosed
US-20110160237-A1 Substituted Heterocyclic Compounds ARQULE, INC. (US) 2011-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160237-A1 Substituted Heterocyclic Compounds MKI67, CCNC, NQO1 TP53 4/4885SMN1; SMN2 1983/4885ALDH1A1 178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.